Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO6864018 in Chronic Hepatitis B
NCT02391805Phase 2Completed
- Sponsor
- Roche
- Start
- May 2015
- Primary completion
- Oct 2017
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of RO6864018 in Chronic Hepatitis B (CHB) (6 arms), sponsored by Roche. Primary endpoint: Percentage of Participants with Adverse Events at 36 weeks. Started May 2015; status: completed.
02
Drugs
RO6864018
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT02391805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02391805.